NEW YORK–(BUSINESS WIRE)–Edgemont Partners, a premier healthcare-dedicated investment bank and leading M&A and capital raising advisor, is pleased to announce that Sarah Pringle has joined the firm as Director to lead and expand its financial sponsor coverage.
David Blume and Jeff Swearingen, Co-founders and Managing Directors of Edgemont, stated: “We are excited for Sarah to join our growing team to head Edgemont’s private equity coverage, one of our most important strategic growth initiatives. We believe that our private equity clients will be best served by a dedicated team exclusively focused on their relationship with Edgemont and the needs of their portfolio companies. As one of the most prominent, respected, and knowledgeable healthcare M&A industry experts based on her experience and network, Sarah is uniquely well qualified to head our PE relationship coverage platform.”
Ms. Pringle brings nearly a decade of healthcare private equity, venture capital and M&A journalism experience. Most recently, she co-authored Axios Pro’s Health Tech Deals newsletter. She previously reported on healthcare M&A and private institutional investments at PE Hub and The Deal.
“I am thrilled to leverage my extensive PE sponsor relationships and healthcare M&A expertise for this newly-established dedicated coverage platform at Edgemont, one of the most active and fastest growing healthcare M&A firms,” said Ms. Pringle. “I’m excited to work with David, Jeff and the entire Edgemont team to grow the Firm’s private equity sponsor coverage amid the rapidly and ever-increasing prominence of private equity in healthcare.”
Ms. Pringle will initially be based in Edgemont’s New York office, reporting to Mr. Blume and Mr. Swearingen. For more information, contact Sarah Pringle at +1 (646) 946-5338.
About Edgemont Partners
Founded in 2001, Edgemont ranks among the most active and best-performing independent healthcare M&A and financial advisors in the U.S. We focus solely on providing expert strategic advice and transaction execution to healthcare and life sciences companies, bringing a steadfast commitment to our clients, driven always to prioritize their best interests. Edgemont’s principals have executed 190+ transactions with an aggregate value of $90 billion+.
